Evidence map›Paper›PMID 31758014›Full record

ArticleScientific reports2019

A mass spectrometry guided approach for the identification of novel vaccine candidates in gram-negative pathogens.

Daniel Hornburg, Tobias Kruse, Florian Anderl, Christina Daschkin, Raphaela P Semper, Kathrin Klar, Anna Guenther, Raquel Mejías-Luque, Nicole Schneiderhan-Marra, Matthias Mann and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Revisiting the Principles of Designing a Vaccine.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  6. Identification ofFrontiers in microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Daniel HornburgMax-Planck-Institute for Biochemistry, Martinsried, Germany.
Tobias KruseInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
Florian AnderlInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
Christina DaschkinInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
Raphaela P SemperInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
Kathrin KlarImevaX GmbH, Munich, Germany.
Anna GuentherNMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany.
Raquel Mejías-LuqueInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-4602-4927
Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany.ORCID http://orcid.org/0000-0001-6785-181X
Matthias MannMax-Planck-Institute for Biochemistry, Martinsried, Germany.ORCID http://orcid.org/0000-0003-1292-4799
Felix MeissnerMax-Planck-Institute for Biochemistry, Martinsried, Germany. meissner@biochem.mpg.de.
Markus GerhardInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany. markus.gerhard@tum.de.ORCID http://orcid.org/0000-0001-9110-3950
German Center for Infection Research · DEMax Planck Institute of Biochemistry · DETechnical University of Munich · DENatural and Medical Sciences Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is the most effective method to prevent infectious diseases. However, approaches to identify novel vaccine candidates are commonly laborious and protracted. While surface proteins are suitable vaccine candidates and can elicit antibacterial antibody responses, systematic approaches to define surfomes from gram-negatives have rarely been successful. Here we developed a combined discovery-driven mass spectrometry and computational strategy to identify bacterial vaccine candidates and validate their immunogenicity using a highly prevalent gram-negative pathogen, Helicobacter pylori, as a model organism. We efficiently isolated surface antigens by enzymatic cleavage, with a design of experiment based strategy to experimentally dissect cell surface-exposed from cytosolic proteins. From a total of 1,153 quantified bacterial proteins, we thereby identified 72 surface exposed antigens and further prioritized candidates by computational homology inference within and across species. We next tested candidate-specific immune responses. All candidates were recognized in sera from infected patients, and readily induced antibody responses after vaccination of mice. The candidate jhp_0775 induced specific B and T cell responses and significantly reduced colonization levels in mouse therapeutic vaccination studies. In infected humans, we further show that jhp_0775 is immunogenic and activates IFNγ secretion from peripheral CD4

Indexed as

Bacterial VaccinesGram-Negative BacteriaMass SpectrometryAntigens, BacterialAntigens, SurfaceBacterial ProteinsComputational BiologyProteomicsReproducibility of ResultsAntigens, BacterialAntigens, SurfaceBacterial ProteinsBacterial Vaccines

Identifiers

PMID31758014
PMCPMC6874673
OpenAlexW2990175506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.